Changhai Hospital
Shanghai, Shanghai Municipality, 200433, China
NCT Number: NCT05508503
To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.
Looking for future studies?
Notify MeAll sexes
Observational
Shanghai, Shanghai Municipality, 200433, China
Usually, colorectal cancers (CRCs) diagnosed in their early stages are curable, especially precancerous lesions (adenomas, polyps) that can be removed during a colonoscopy.However, due to low patient compliance and limited resources, colonoscopy is not feasible for screening the average-risk population. gFOBT/FIT are limited by their low sensitivity and high false-positive rate. Compared to colonoscopy and stool DNA tests, blood-based methylation tests showed greater patient compliance and convenience. Hypermethylated NTMT1 and MAP3K14-AS1 were found in multiple cohorts of CRC samples in our previous study. In this study, we aimed to evaluate the effectiveness and accuracy of the ctDNA dual-target(NTMT1 and MAP3K14-AS1) test kit in 5 tertiary hospitals around china for the detection of colorectal cancer and advanced adenomas. Fecal immunochemical test (FIT) will also privided to participants in the study. Sanger sequencing would be performed to evalute the accuracy of the dual-target methylation detection test kit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
Fecal immunochemical test(optional)
Time frame: Through study completion, an average of 1 year.
Sensitivity (for CRC and\\or advanced precancerous neoplasm) of this blood-based methylation dual-target test. A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. Other clinically acceptable diagnostic criteria for non-intestinal diseases.
Time frame: Through study completion, an average of 1 year.
Specificity (for CRC and\\or advanced precancerous neoplasm) of this blood-based methylation dual-target test. A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. Other clinically acceptable diagnostic criteria for non-intestinal diseases.
Time frame: Through study completion, an average of 1 year.
Accuracy of the kit for methylation detection. Validation of the methylation status of MTNT1 and MAP3K14-AS1 by Sanger sequencing.
Time frame: Through study completion, an average of 1 year.
Sensitivity when combined the blood-based methylation dual-target test with FIT
Time frame: Through study completion, an average of 1 year.
Specificity when combined the blood-based methylation dual-target test with FIT
Changhai Hospital
Other
Validation of a ctDNA Methylation-based Dual-target Test for the Detection of Colorectal Cancer: a Multicenter Clinical Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07678099
Breast Cancer, Breast Diseases
Istanbul, Uskudar, Turkey (Türkiye)
View Trial DetailsNCT07321548
Colonic Diseases, Colorectal Adenoma
Hong Kong
View Trial DetailsNCT04636619
Colonic Diseases, Colonic Polyp
Valladolid, Spain
View Trial DetailsNCT05740137
Colonic Diseases, Colorectal Adenoma
Holbæk, Denmark
View Trial Details